Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.
Most of the his research activity in the first 15 years were related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in mono-therapy, or as an element of Z-BEAM conditioned ASCT.
In the last decade, establishing MCM, a private research facility, allowed the lymphoma team to take part in over 50 clinical trials, including phase I and phase I followed by expansion cohorts. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars. At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs.
Being a member of ASH, ASCO, PLRG and EMCLN, his papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc.